CD274 and neoplasm: Tumor intrinsic mechanisms of ICB-resistance, such as upregulation of PD-L1, downregulation of MHC-I, or increase of oncogenic, β-catenin signaling pathway might also contribute to the failure of ICB-monotherapy [15].